Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access               Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain EXEL message board posts where the ticker symbol EXEL has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest EXEL SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000040 Size: 12 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000039 Size: 12 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000038 Size: 12 KB
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-18-001410 (34 Act)  Size: 11 KB
2018-03-05 000-30235
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000034 Size: 11 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000033 Size: 12 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000032 Size: 16 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000031 Size: 14 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000030 Size: 12 KB
S-8  Documents Securities to be offered to employees in employee benefit plans
Acc-no: 0000939767-18-000024 (33 Act)  Size: 338 KB
2018-02-26 333-223225
More EXEL SEC Filings

Related news from
Fri, 23 Mar 2018
06:05:00 +0000
Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Exelixis, Inc. today announced that its partner Ipsen has received a positive opinion from the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , for CABOMETYX® 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma .
Thu, 15 Mar 2018
12:05:28 +0000
See what the IHS Markit Score report has to say about Exelixis Inc.
Thu, 15 Mar 2018
12:00:00 +0000
Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (Cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma
Exelixis, Inc. today announced it has completed the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for CABOMETYX® tablets as a treatment for patients with previously treated advanced hepatocellular carcinoma .
Tue, 13 Mar 2018
15:29:00 +0000
Why Exelixis Fell 14.9% in February
Slowing growth has investors worried.
Sat, 10 Mar 2018
16:00:00 +0000
Top 5 Biotech Stocks for 2018
Biotech can be risky, but these top biotech stocks have stable track records.
Fri, 09 Mar 2018
12:55:11 +0000
Edited Transcript of EXEL earnings conference call or presentation 26-Feb-18 10:00pm GMT
Q4 2017 Exelixis Inc Earnings Call
Tue, 06 Mar 2018
21:05:00 +0000
Exelixis Announces Webcasts of Investor Conference Presentations in March
Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the
Wed, 28 Feb 2018
19:26:01 +0000
5 Biotech Stocks to Sell Amid the Latest Slaughter
Stocks are under fresh pressure after new Federal Reserve chairman Jerome Powell sounded a hawkish note in his first appearance before Congress this week. The odds of four quarter-point rate hikes is now rising fast, pressuring long-term Treasury yields higher, bringing back the headwind that pushed stocks into a correction earlier this month.
Tue, 27 Feb 2018
21:27:59 +0000
These Biotechs Diverge After Biggest Moneymakers Lag Expectations
Exelixis and Clovis shares diverged Tuesday after each reported lackluster sales of their biggest cancer drugs in the fourth quarter.
Tue, 27 Feb 2018
21:09:00 +0000
Exelixis in Transition
The biotech posted a disappointing quarter, but there's more growth ahead.
Tue, 27 Feb 2018
20:49:08 +0000
Exelixis (EXEL) Q4 Earnings Meet Estimates, Revenues Beat (revised)
Exelixis' (EXEL) fourth-quarter results were positive wherein sales beat estimates on the back of Cabometyx growth while earnings met estimates.
Tue, 27 Feb 2018
14:53:02 +0000
Perrigo (PRGO) Postpones Q4 Earnings Results, Shares Down
Perrigo (PRGO) to reschedule fourth-quarter 2017 and full-year earnings results. However, the company releases preliminary unaudited numbers for the full year.
Tue, 27 Feb 2018
02:56:00 +0000
Exelixis Inc. (EXEL) Q4 2017 Earnings Conference Call Transcript
EXEL earnings call for the period ending December 31, 2017.
Tue, 27 Feb 2018
01:00:00 +0000
Exelixis Announces Collaborator Daiichi Sankyo’s Submission of Regulatory Filing for Esaxerenone (CS-3150) in Japan
Exelixis, Inc. today announced that its partner Daiichi Sankyo Company, Limited has submitted its regulatory application for esaxerenone as a treatment for patients with hypertension to the Japanese Pharmaceutical and Medical Devices Agency.
Mon, 26 Feb 2018
22:12:31 +0000
Exelixis meets 4Q profit forecasts
On a per-share basis, the South San Francisco, California-based company said it had net income of 12 cents. The results matched Wall Street expectations. The average estimate of eight analysts surveyed ...
Mon, 26 Feb 2018
21:58:06 +0000
Cancer Biotech Plunges Despite Narrowly Beating Quarterly Sales Views
Exelixis reported 12 cents earnings per share on $120.1 million in sales for the fourth quarter.
Mon, 26 Feb 2018
21:05:00 +0000
Exelixis Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Exelixis, Inc. today reported financial results for the fourth quarter and full year of 2017 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
Mon, 26 Feb 2018
18:15:00 +0000
Exelixis, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Exelixis, Inc. (NASDAQ: EXEL ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 26, 2018 at 5:00 PM Eastern Time. ...
Mon, 26 Feb 2018
16:14:05 +0000
Exelixis Q4 Earnings Outlook
Exelixis (NASDAQ: EXEL ) will be releasing its next round of earnings Monday. For all of the relevant information, here is your guide for today's Q4 earnings announcement. Earnings and Revenue Wall Street ...

"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "VF is a great group of value seeking investors, who are most generous in sharing their research, news, business expertise, and investment experience. It is an invaluable resource, and brings many 'lessons learned' to the group." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards